HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
HCW Biologics GAAP EPS of -$2.02, revenue of $15.60M [Seeking Alpha]
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer